

Application No. 10/528,659

2

Docket No.: 80176(302730)

Amendment dated January 5, 2009

Reply to Notice of Non-Compliant Amendment dated December 16, 2008

Amendments to the Claims

1. (Cancelled)

2. (Cancelled)

3. (Currently amended) A method for assessing ~~diagnosing~~ the genetic risk for hypertension in a human male subject, the method comprising the following steps (i) to (iii):

(i) ~~analyzing the two or more polymorphisms selected from the group consisting of the following (1) to (3) (4) in a nucleic acid sample from the human male subject, the polymorphisms comprising:~~

(1) a polymorphism at the base number position 1648 of the glycoprotein Ia gene;

(2) a polymorphism at the base number position 190 of the chemokine receptor 2 gene; and

(3) a polymorphism at the base number position 1100 of the apolipoprotein C-III gene; and

~~(4) a polymorphism at the base number position 825 of G-protein $\beta 3$ subunit gene.~~

(ii) determining, based on the information about polymorphism which was obtained in the step (i), the genotype in the nucleic acid sample from the human male subject; and

(iii) assessing, based on the genotype determined, a genetic risk for hypertension in the human male subject.

4. – 8. (Cancelled)

9. (Currently Amended) A method for assessing the genetic risk for hypertension in a human male subject, the method comprising the following steps (i) to (iii):

Application No. 10/528,659

3

Docket No.: 80176(302730)

Amendment dated January 5, 2009

Reply to Notice of Non-Compliant Amendment dated December 16, 2008

(i) analyzing the polymorphisms (1) to (3) in a nucleic acid sample from the human male subject, the polymorphisms comprising:

(1) a polymorphism at the base number position 1648 of the glycoprotein Ia (GPIa) gene, wherein the polymorphism is GPIa A1648G ;

(2) a polymorphism at the base number position 190 of the chemokine receptor 2 (CCR2) gene, wherein the polymorphism is CCR2 G190A; and

(3) a polymorphism at the base number position 1100 of the apolipoprotein C-III (apo CIII) gene, wherein the polymorphism is apoCIII C1100T; and

(ii) determining, based on the information about polymorphism which was obtained in the step (i), the genotype in the nucleic acid sample from the human male subject; and

(iii) assessing, based on the genotype determined determine, a genetic risk for hypertension in the human male subject.

DC 253226.1